Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101

Journal of the National Cancer Institute

Volumn 88, Issue 18, 1996, Pages 1276-1284

  Sredni, Benjamin ^a   Tichler, Thomas ^b   Shani, Adi ^c   Catane, Rafael ^d   Kaufman, Bella ^d   Strassmann, Gideon ^e   Albeck, Michael ^a   Kalechman, Yona ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c KAPLAN HOSPITAL   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e Otsuka Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LUNG CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; SARCOMA;

EID: 0029760061     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.18.1276     Document Type: Article

References (35)

1. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. The use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comment citation in Medline]. N Engl J Med 1988;319:1676-80.
2. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
3. Gansbacher B, Zier K, Daniels G, Cronin K, Bannerji R, Gilboa E. Murine interleukin-4 displays potent antitumor activity in vivo. J Exp Med 1990;172:1217-24.
4. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991;12:256-7.
5. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM. Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991;12:392-5.
6. Kullberg M, Pearce E, Hieny S, Sher A, Berzofsky J. Infection with Schistosoma mansoni alters TH1/TH2 cytokine responses to a non-parasite antigen. J Immunol 1992;148:3264-70.
7. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
8. Schoof DD, Terashima Y, Peoples GE, Goedegebuure PS, Andrews JV, Richie JP, et al. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 1993;150:114-23.
9. Yamamura M, Modlin RL, Ohmen JD, Moy RL. Local expression of antiinflammatory cytokines in cancer. J Clin Invest 1993;91:1005-10.
10. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, et al. Loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-83.
11. Sredni B, Caspi RR, Klein A, Kalechman Y, Danzinger Y, Ben Ya'akov M, et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987;330:173-6.
12. Sredni B, Kalechman Y, Albeck M, Gross O, Aurbach D, Sharon P, et al. Cytokine secretion effected by synergism of the immunodulator AS101 and the protein kinase C inducer bryostatin. Immunology 1990;70:473-7.
13. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Seghal SN, et al. Radioprotective effects of the immunomodulator AS101. J Immunol 1990;145:1512-7.
14. Sredni B, Caspi RR, Lustig S, Klein A, Kalechman Y, Danziger Y, et al. The biological activity and immunotherapeutic properties of AS 101, a synthetic organotellurium compound. Nat Immun Cell Growth Regul 1988; 7:163-8.
15. Kalechman Y, Sotnik-Barkai I, Albeck M, Sredni B. The effect of AS101 on the reconstitution of T-cell reactivity following irradiation or cyclophosphamide treatment. Exp Hematol 1992;20:1302-8.
16. Kalechman Y, Gafter U, Sotnik-Barkai I, Albeck M, Sredni B. Mechanism of radioprotection conferred by the immunomodulator AS101. Exp Hematol 1993;21:150-5.
17. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Horwith G, et al. Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res 1991;51:1499-503.
18. Kalechman Y, Shani A, Sotnik-Barkai I, Albeck M, Sredni B. The protective role of ammonium trichloro[dioxoethylene-O,O′]tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Cancer Res 1993;53:5962-9.
19. Shani A, Tichler T, Catane R, Gurwith M, Rozenszajn LA, Gezin A, et al. Immunologic effects of AS101 in the treatment of cancer patients. Nat Immun Cell Growth Regul 1990;9:182-90.
20. Sredni B, Catane R, Shani A, Gezin A, Levi E, Schlesinger M, et al. Phase I study of AS101 (an organotellurium compound) in patients with advanced malignancies. In: Rubinstein E, Adam A, editors. Recent advances in chemotherapy. Jerusalem: E. Lewin-Epstein, 1990;851.1-851.4.
21. Sredni B, Albeck M, Tichler T, Shani A, Shapira J, Bruderman I, et al. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 1995;13:2342-53.
22. Schoof D, Selleck C, Massaro A, Jung S, Eberlein T. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 1990;50:1138-43.
23. Steel RG, Torrie JH. Principles and procedures of statistics. 2nd ed. New York: McGraw-Hill, 1980.
24. Kendall M, Stuart A. The advanced theory of statistics. Vol 2. New York: Macmillan, 1979.
25. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993;14:335-8.
26. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and 1L-2. J Immunol 1992;148:92-8.
27. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil M, et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol 1992;149:3495-502.
28. Broder S, Waldmann TA. The suppressor-cell network in cancer (first of two parts). N Engl J Med 1978;299:1281-4.
29. Hersh EM, Oppenheim JJ. Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med 1965;273:1006-12.
30. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/-Th/2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-18.
31. Murphy EE, Terres G, Macatonia SE, Hsieh CS, Mattson J, Lanier L, et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223-31.
32. North RJ, Awwad M, Dunn PL. The immune reponse to tumors. Transplant Proc 1989;21:575-7.
33. Bloom BR, Salgame P, Diamond B. Revisiting and revising suppressor T cells. Immunol Today 1992;13:131-6.
34. Lotzova E. Cytotoxicity and clinical application of activated NK cells. Med Oncol Tumor Pharmacother 1989;6:93-8.
35. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.